The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer

Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non‐small‐cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD‐1) and its ligand (PD‐L1), have remarkable antitumor efficacy and have been appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fajiu, Chen, Ying, Wu, Juanjuan, Li, Chenghong, Chen, Shi, Zhu, Ziyang, Qin, Wei, Liu, Min, Hu, Bingzhu, Liu, Shuang, Zhong, Wenzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215714/
https://www.ncbi.nlm.nih.gov/pubmed/35774424
http://dx.doi.org/10.1002/cdt3.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215714/
https://www.ncbi.nlm.nih.gov/pubmed/35774424
http://dx.doi.org/10.1002/cdt3.19

Ejemplares similares